1. Clinical and Epidemiologic Features of Mycoplasma pneumoniae Infection Among Adults Hospitalized with Community-acquired Pneumonia.
- Author
-
Kutty PK, Jain S, Diaz MH, Self WH, Williams D, Zhu Y, Grijalva CG, Edwards KM, Wunderink RG, Winchell J, and Hicks LA
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Macrolides therapeutic use, Prospective Studies, Aged, Adolescent, Young Adult, Drug Resistance, Bacterial, Mycoplasma pneumoniae isolation & purification, Mycoplasma pneumoniae genetics, Mycoplasma pneumoniae drug effects, Community-Acquired Infections epidemiology, Community-Acquired Infections microbiology, Pneumonia, Mycoplasma epidemiology, Pneumonia, Mycoplasma microbiology, Pneumonia, Mycoplasma drug therapy, Pneumonia, Mycoplasma complications, Hospitalization statistics & numerical data, Anti-Bacterial Agents therapeutic use
- Abstract
Background/Purpose: The burden and epidemiology of Mycoplasma pneumoniae (Mp) community-acquired pneumonia (CAP) among hospitalized U. S. adults (≥ 18 years) are poorly understood. Methods: In the Etiology of Pneumonia in the Community (EPIC) study, we prospectively enrolled 2272 adults hospitalized with radiographically-confirmed pneumonia between January 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp by real-time polymerase chain reaction (PCR). Clinical and epidemiological features of Mp-PCR-positive and -negative adults were compared using logistic regression. Macrolide susceptibility was assessed by genotyping isolates. Results: Among 2272 adults, 43 (1.8%) were Mp-PCR-positive (median age: 45 years); 52% were male, and 56% were non-Hispanic white. Only one patient had Mp macrolide resistance. Four (9%) were admitted to the intensive care unit (ICU). No in-hospital deaths were reported. Of the 9 (21%) who received an outpatient antibiotic ≤5 days pre-admission, 2 (22%) received an antibiotic with Mp activity. Variables significantly associated with higher odds of Mp detection included age {18-29 years [(adjusted odds ratio (aOR): 11.7 (95% confidence interval (CI): 5.1- 26.6) versus ≥50 years]} and radiographic lymphadenopathy [aOR: 3.5 (95% CI: 1.2- 9.3)]. Conclusions: M. pneumoniae , commonly known to cause "walking pneumonia", was detected among hospitalized adults, with the highest prevalence among young adults. Although associated with clinically non-specific symptoms, approximately one out of every ten patients were admitted to the ICU. Increasing access to M. pneumoniae point-of-care testing could facilitate targeted treatment and avoid hospitalization., Competing Interests: Competing Interests: Dr. Edwards reports grants from CDC, during the conduct of the study; grants from NIH, other from Bionet, other from IBM, other from Sanofi, other from X-4 Pharma, other from Sequirus, other from Moderna, other from Pfizer, other from Merck, outside the submitted work. Dr. Grijalva reports personal fees from Sanofi, personal fees from Merck, personal fees from Pfizer, grants from Sanofi, grants from Campbell Alliance, grants from Centers for Disease Control and Prevention, grants from the National Institutes of Health, grants from Agency for HealthCare Research and Quality, other from Food and Drug Administration, outside the submitted work. Dr. Zhu reports grants from CDC, during the conduct of the study. Dr. Self reports grants from the Centers for Disease Control and Prevention during the conduct of the study, grants and personal fees from Merck & Co., grants from Pfizer, and personal fees from Aerpio Pharmaceuticals outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The author(s).)
- Published
- 2024
- Full Text
- View/download PDF